1. A new asthma medication was just approved. Four high-quality clinical trials show that the drug increases forced expiratory volume in 1 second (FEV₁) and peak flow rate in children with uncontrolled asthma who are currently receiving SABA therapy as needed. Based on this evidence, you recommend that the pharmacy benefit manager (PBM) you work for add this to the preferred drug list (PDL). 
2. 
   
3. Provide a Strength of Recommendation Taxonomy (SORT) rating for this recommendation and justify the rating you select.

Answer rating: 100% (QA)

Answer1 Based on the evidence provided it seems reasonable to recommend that the PBM add the new ast... View the full answer